Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
The prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients.
To describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS.
Clinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018.
We included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P = .002) and progression-free survival (P = .014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis.
A retrospective study at a single cancer center.
MF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions.Le texte complet de cet article est disponible en PDF.
Key words : African American, cutaneous lymphoma, hyperpigmented MF, hypopigmented MF, MF, racial disparity, skin of color, survival analysis
Abbreviations used : CI, DSS, HR, LDH, MF/SS, MSKCC, OR, OS, PFS
| Funding sources: Supported in part through the National Institutes of Health National Cancer Institute Cancer Center support grant P30 CA008748.
| Conflicts of interest: Dr Horwitz has received research funding, grant support, honoraria and consulting fees from ADCT Therapeutics, Aileron, Forty-Seven Infinity/Verastem Kyowa-Hakka-Kirin, Millennium/Takeda, and Seattle Genetics; research and grant support from Celgene and Trillium; and honoraria and consulting fees from Affimed, Angimmune, Beigene, Corvus, Innate Pharma, Kura, Merck, Miragen, Mundipharma, Portola, and Syros Pharmaceutical. Dr Moskowitz received honoraria from Seattle Genetics; served as a consultant or in an advisory role for Seattle Genetics, Kyowa Hakko Kirin Pharma, Miragen Therapeutics, Takeda Pharmaceuticals, ADC Therapeutics, Cell Medica, Bristol-Myers Squibb, and Erytech PharmaResearch; and received funding through her institution from Incyte, Seattle Genetics, Merck, and Bristol-Myers Squibb. Dr Geller, Dr Lebowitz, Dr Pulitzer, Dr Dusza, and Dr Myskowski have no conflict of interest to declare.
| Previously presented at the European Organisation for Research and Treatment of Cancer (EORTC-CLTF) meeting in Athens, Greece, on September 26th, 2019.